Uncategorized
Visual acuity gain with anti-VEGF for pathologic myopia not maintained at 5 years
VIENNA — Five-year results of a study evaluating the safety and efficacy of bevacizumab in eyes with choroidal neovascularization secondary to pathologic myopia showed that the mean visual gain achieved at 2 years is not maintained. “We should now investigate the prognostic factors as we did with AMD,” Paolo Lanzetta, MD, said at the Advanced Retinal Therapy meeting. Phase 3 trials showed efficacy of Lucentis (ranibizumab, Novartis/Genentech) and Eylea (aflibercept, Bayer HealthCare/Regeneron) in inducing significant improvement in best corrected visual acuity over a shorter study duration.